Effect of microRNA-155 on regulation of angiogenesis in diabetic rats with cerebral ischemic injury

AIM: To evaluate the effect of microRNA-155(miRNA-155) on the regulation of angiogenesis in diabetic rats with cerebral ischemic injury. METHODS: Adult male Sprague-Dawley rats were randomly divided into 5 groups:sham group, cerebral ischemia group, diabetic cerebral ischemia group, diabetic cerebral ischemia+miRNA-155 inhibitors group and diabetic cerebral ischemia+scramble group. Diabetes model was made by injection of streptozocin and permanent cerebral ischemic model was developed by suture-occluded method. The scores of neurological deficit and infarct volume were estimated at 24 h after cerebral ischemia. miRNA-155 level was detected by real-time polymerase chain reaction. The expression of platelet endothelial cell adhesion molecule-1(PECAM-1/CD31) and vascular endothelial growth factor(VEGF) was detected by Western blotting. RESULTS: miRNA-155 inhibitor significantly reduced miRNA-155 levels in the ischemic cortex(P<0.05), improved the scores of neurological deficit, reduced infarction size and upregulated the levels of CD31 and VEGF(P<0.05). CONCLUSION: miRNA-155 has a critical role in the regulation of angiogenesis in diabetic rats with cerebral ischemia. Down-regulation of miRNA-155 using miRNA-155 inhibitor attenuates brain infarct injury in diabetic rats.     

优质高产杂交中籼新组合辐优155的选育与应用研究

[目的]为杂交中籼新组合辐优155的推广应用提供参考.[方法]通过辐优155经安徽省2007、2008年2年区试和2009年生试,比较辐优155与对照品种Ⅱ优838主要农艺性状、产量、稻米品质及抗性,并分析了其大田栽培技术及制种技术要点,以探讨其生产潜力及推广价值.[结果]辐优155是安徽省铜陵县农业科科学研究所用辐88A与恢155配组育成的杂交中籼新组合,具有株型适中、穗大粒多、米质优、抗稻瘟病、中抗白叶枯病等特点,2010年通过安徽省农作物品种审定委员会审定.[结论]辐优155产量高,品质好,适宜在安徽全省种植.     

Celastrol blocks cell cycle of A549 cells by regulating miR-17-5p/miR-155-5p and targeting cyclin D1

AIM: To investigate the effect of celastrol on the cell cycle of human lung adenocarcinoma A549 cells and to probe into its mechanisms.METHODS: A549 cells were exposed to celastrol at gradient concentrations. The cell viability and apoptosis were detected by MTT assay and flow cytometry, respectively, and the median lethal concentration (LC₅₀) of celastrol was screened. The A549 cells were treated with celastrol at LC₅₀, and the cell cycle was detected by flow cytometry. The expression of cyclin D1 was determined by Western blot, and the expression of microRNA (miR)-17-5p and miR-155-5p was detected by real-time PCR. The correlation between cyclin D1 and miR-17-5p or miR-155-5p was predicted by bioinformatics software. After miR-17-5p mimics/miR-155-5p mimics/mutant-miR-17-5p/mutant-miR-155-5p and pcDNA-GFP-cyclin D1-3'UTR were cotransfected into the A549 cells, the changes of GFP expression were evaluated by fluorescence microscopy and flow cytometry. Finally, after miR-17-5p mimics or miR-155-5p mimics were transfeced into the A549 cells, the expression of miR-17-5p and miR-155-5p was detected by real-time PCR, and the protein level of cyclin D1 was determined by Western blot. RESULTS: With the increasing concentration of celastrol, the viability inhibition rate and apoptotic rate of the A549 cells were increased, indicating that celastrol effectively inhibited the growth of A549 cells and induced apoptosis. The LC₅₀ of celastrol was almost 3 μmol/L. After treatment with celastrol at LC₅₀, the A549 cell cycle was arrested at G₁ phase, the protein expression of cyclin D1 was down-regulated (P<0.01), and the expression levels of miR-17-5p and miR-155-5p were significantly increased (P<0.01). The results of bioinformatics software prediction indicated that there were binding sites for miR-17-5p and miR-155-5p in the 3'-UTR of cyclin D1. After cotransfected with miR-17-5p or miR-155-5p and pcDNA-GFP-cyclin D1-3'UTR into the A549 cells, the expression of GFP declined (P<0.05). After miR-17-5p or miR-155-5p mimics were transfected into A549 cells, the results of real-time PCR showed this treatment significantly increased the miRNA expression (P<0.01), and the results of Western blot showed the transfection inhibited cyclin D1 expression (P<0.01).CONCLUSION: Celastrol blocks the A549 cells at G₁ phase, inhibits the viability and induces apoptosis, which may be caused by up-regulating the expression of miR-17-5p and miR-155-5p, and then down-regulating cyclin D1 expression. This study provides a new theoretical basis for the treatment of non-small-cell lung cancer with celastrol.     

Effects of miR-155 over-expression on expression of inflammatory factors and indolamine 2, 3-dioxygenase in microglial BV-2 cells

AIM:To explore the effect of microRNA-155(miR-155)over-expression on the expression of inflammatory factors and indolamine 2, 3- dioxygenase (IDO) in the microglial BV-2 cells. METHODS:For over-expression of miR-155, the BV-2 cells were transfected with lentiviral vector carrying mmu-miR-155. The expression of inflammatory factors was detected by cytometric bead array system (CBA). The mRNA expression of inflammatory factors and IDO was analyzed by real-time PCR. The protein levels of suppressor of cytokine signalling 1 (SOCS1), p-p38 MAPK and IDO were determined by Western blot. RESULTS:The expression of miR-155 was up-regulated in the BV-2 cells transfected with lentiviral vector carrying mmu-miR-155 compared with LPS treatment group (P<0.01). The miR-155 over-expression promoted the secretion of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), monocyte chemotactic protein-1 (MCP-1) and IL-10, and inhibited the secretion of IL-12. The miR-155 over-expression increased the mRNA expression of IL-6, TNF-α, IL-10 and IDO, also increased the protein levels of IDO and p-p38 MAPK, but decreased the protein expression of SOCS1 (P<0.01). LPS promoted the secretion of IL-6, TNF-α, MCP-1 and IL-12, also increased the mRNA expression of IL-6, TNF-α and IDO, meanwhile, increased the protein levels of IDO, p-p38 MAPK and SOCS1 (P<0.01). CONCLUSION:Over-expression of miR-155 promotes the secretion of related imflammatory factors and protein expression of IDO in microglial BV-2 cells mediated with SOCS1 and p38 MAPK signaling pathway.     

Effects of glucocorticoid on miRNA-155 expression in CD4+T cells of asthmatic mice

AIM:To investigate the effects of glucocorticoid on the regulation of microRNA-155 (miRNA-155) expression in the CD4⁺ T cells of asthmatic mice. METHODS:The ovalbumin (OVA)-induced asthma mouse model was established and the mice were treated with glucocorticoid. The effects of glucocorticoid on the pulmpnary histopathological changes, the expression of miRNA-155 in the lung tissues and CD4⁺T cells, and the levels of cytokines in the bronchoal-veolar lavage fluid (BALF) were evaluated. RESULTS:The results of RT-qPCR showed that the expressions of miRNA-155 in the lung tissues and CD4⁺T cells from the spleen of asthmatic mice were significantly increased, and the level of miRNA-155 in the CD4⁺T cells was significantly increased with the increase in the allergen exposure time (P<0.01). HE and PAS staining showed that OVA significantly increased inflammatory cell infiltration as compared with control group, and the peribronchial and perivascular inflammation and mucus secretion of proliferative goblet cells were significantly reduced after glucocorticoid treatment. Glucocorticoid treatment inhibited the increase in the proportion of CD4⁺ CD8^- cells in the spleen and decreased the accumulation of CD4⁺ T cells in the lung tissues of asthmatic mice (P<0.01). After glucocorticoid treatment, the levels of interleukin-4 (IL-4), IL-5 and IL-13 in BALF were decreased, while the level of interferon-γ was increased significantly (P<0.01). CONCLUSION:Glucocorticoid reduces the accumulation of CD4⁺ T cells and inhibits the expression of miRNA-155 in the lung tissues and spleen CD4⁺ T cells of asthmatic mice.     

MiR-155在脂多糖诱导的RAW264.7巨噬细胞炎症反应中的表达研究

[目的]探讨miR-155在脂多糖(LPS)诱导的RAW264.7巨噬细胞炎症反应中的表达及糖皮质激素(GCs)的干预影响。[方法]体外培养RAW 264.7巨噬细胞,分别用浓度为10.0、1.0、0.1μg/ml LPS刺激RAW 264.7巨噬细胞,于2、6、12、24、36 h 5个时间点收集上清用ELISA检测白介素-6(IL-6)蛋白浓度;实时定量-PCR检测miR-155在2、6、12、36 h 4个时间点的表达变化。[结果]IL-6在各浓度LPS处理组、各时间点其含量均高于对照组(CK);miR-155的表达在各时间点LPS组均高于LPS+GCs和CK。[结论]LPS可以诱导RAW264.7巨噬细胞的炎症反应,炎症反应时miR-155高表达,糖皮质激素可抑制miR-155的表达。     

肝细胞癌中miR-155与CD44v6表达及相关性研究

目的探讨mi R-155及CD44v6在肝细胞癌（HCC）中表达及其相关性。方法采用q RT-PCR检测32例HCC患者癌组织及癌旁组织中mi R-155及CD44v6 m RNA表达,用免疫组化法检测CD44v6蛋白表达,分析两者间相关性及其与HCC临床病理特征关系。结果 HCC癌组织CD44v6蛋白及CD44v6、mi R-155m RNA较癌旁组织表达升高（P〈0.05）,IIIIV级及侵犯脉管的癌组织中mi R-155和CD44v6 m RNA表达较高（P〈0.05）。mi R-155和CD44v6 m RNA表达呈正相关（P〈0.05）。结论 mi R-155和CD44v6均参与HCC发生及发展。     

Antisense oligonucleotides targeting seed sequence of miR-155 and its applications in multiple myeloma

AIM：To investigate the role of tiny antisense nucleic acid against miR-155 (tiny antimiR-155, t-antimiR-155) in multiple myeloma cells. METHODS：According to the seed sequence of miR-155, t-antimiR-155 was designed and synthesized. t-antimiR-155 was transfected by LipofectamineTM 2000 into RPMI-8266 cells. The cells were divided into t-antimiR-155 group, scrambled control (SCR) group and blank control group. The growth-inhibitory potencies were measured by MTT assay. The ability of cell colony formation was detected by cell colony formation assay. The cell apoptosis was assessed by flow cytometry with annexin V/PI double staining. RESULTS：The best concentration and time were 0.4 μmol/L and 48 h, respectively. The cell colony forming experiment showed that the circumstances of forming cell community in t-antimiR-155 group was weaker than that in SCR group, and the colony formation inhibitory rate of former was significant higher than the latter. Compared with SCR group, the cell apoptosis in t-antimiR-155 group significantly increased. CONCLUSION：The t-antimiR-155 inhibits the progression of multiple myeloma cells by interfering with miR-155. miR-155 may serve as a potential target in gene therapy for treating multiple myeloma.     

红粒春小麦穗发芽抗性鉴定及相关分子标记的有效性验证

为了筛选出能鉴定红粒小麦穗发芽抗性的分子标记及抗穗发芽的种质材料,检测了67份红粒春小麦品种(系)的发芽指数,并利用4个与穗发芽抗性相关的标记(Vp1B3、Xgwm155、Xwmc468和Xgwm397)对这67份品种(系)进行了PCR扩增,分析了扩增片段与发芽指数的关系.结果表明,在67个红粒春小麦品种(系)中,12...     

Time-course changes in the expression levels of miR-122, -155, and -21 as markers of liver cell damage,inflammation, and regeneration in acetaminophen-induced liver injury in rats

Drug-induced liver injury (DILI) is a significant threat to patient health and a major concern during drug development. Recently, multiple circulating microRNAs (miRNAs) have been reported to be potential biomarkers for DILI. To adapt and validate miRNAs for clinical use, we investigated the time-course changes in miR-122 expression levels in an acetaminophen-induced liver injury model in rats. In addition, miR-155 and miR-21 were evaluated as makers of inflammation and regeneration, respectively, to characterize liver status. Our results revealed that miR-122 is an early and sensitive biomarker of hepatocellular injury at a stage when alanine transaminase, aspartate transaminase, and total bilirubin were not detectable. However, no significant differences in the expression levels of other miRNAs (miR-155 and -21) were observed between treatment and vehicle groups. Collectively, these time-course changes in the expression levels of miRNAs may be useful as markers for clinical decision-making, in the diagnosis and treatment of DILI.